A Phase III randomised, double-blind, multicentre study to evaluate the safety and efficacy of 1592U89 (abacavir) in human immunodeficiency virus 1-infected patients with aquired immune deficiency syndrome dementia complex
2011 ◽
Vol 6
(4)
◽
pp. 419-435
◽
1990 ◽
Vol 66
(2)
◽
pp. 246-250
◽
2012 ◽
Vol 72
(5)
◽
pp. 361-370
◽
2015 ◽
Vol 22
(1)
◽
pp. 3-8
◽
2014 ◽
Vol 109
(6)
◽
pp. 738-747
◽
1994 ◽
Vol 157
(1)
◽
pp. 3
◽
2006 ◽
pp. 459-470